Literature DB >> 29675809

Is cytokine-release syndrome the cause of rituximab treatment-related infusion reactions in children with nephrotic syndrome? Impact of anti-rituximab antibodies.

Shuichiro Fujinaga1, Tomohiko Nishino2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29675809     DOI： 10.1007/s00467-018-3960-0

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN： 0931-041X            Impact factor:   3.714


× No keyword cloud information.
  3 in total

1.  Infusion reactions associated with rituximab treatment for childhood-onset complicated nephrotic syndrome.

Authors:  Koichi Kamei; Masao Ogura; Mai Sato; Shuichi Ito; Kenji Ishikura
Journal:  Pediatr Nephrol       Date:  2018-02-09       Impact factor: 3.714

2.  Single infusion of low-dose ofatumumab in a child with complicated nephrotic syndrome with anti-rituximab antibodies.

Authors:  Shuichiro Fujinaga; Koji Sakuraya
Journal:  Pediatr Nephrol       Date:  2017-12-16       Impact factor: 3.714

3.  Development of antirituximab antibodies in children with nephrotic syndrome.

Authors:  Yo Han Ahn; Hee Gyung Kang; Jiwon M Lee; Hyun Jin Choi; Il-Soo Ha; Hae Il Cheong
Journal:  Pediatr Nephrol       Date:  2014-03-12       Impact factor: 3.714
  3 in total
  2 in total

1.  The Curative Effect of Shuangshen Decoction Combined with Immunological Preparations in the Treatment of Pediatric Nephrotic Syndrome and Its Influence on the Rate of Complicated Infection and Recurrence.

Authors:  Naiqin Han; Jialing Xie; Qiuying Li; Haixia Li; Xiuzhen Wang; Ying Sheng
Journal:  Comput Math Methods Med       Date:  2022-01-27       Impact factor: 2.238

2.  Anti-rituximab antibodies in pediatric steroid-dependent nephrotic syndrome.

Authors:  Quentin Bertrand; Sabine Mignot; Theresa Kwon; Anne Couderc; Anne Maisin; Alexandra Cambier; Véronique Baudouin; Marine Peyneau; Georges Deschênes; Julien Hogan; Claire Dossier
Journal:  Pediatr Nephrol       Date:  2021-06-16       Impact factor: 3.714
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.